secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001104659-22-098047
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics appoints new CFO, CSO, and SVP of Corporate Affairs
------------------------------------------------------------------------

- Peter Pfreundschuh named CFO effective Sept 19, 2022; base salary $455K, target bonus 40%, 200K option + 125K RSU.
- Todd Carter promoted to CSO effective Sept 19, 2022; base salary $410K, target bonus 40%, 165K option.
- Trista Morrison appointed SVP of Corporate Affairs and Chief of Staff to CEO effective Sept 19, 2022.
- Julie Burek remains VP of Finance; Pfreundschuh assumes principal financial and accounting officer roles.
- Equity grants for Pfreundschuh are inducement awards under Nasdaq Listing Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922098047/0001104659-22-098047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922098047/tm2225311d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-098047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer